JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,150 from $1,200 and keeps an Overweight rating on the shares. The firm updated estimates following the recent Eylea biosimilar updates. It views the recent weakness in the shares as a buying opportunity. While lowering Eylea forecasts, JPMorgan expects Eylea HD will continue to ramp steadily while pricing will likely remain manageable with only one near-term biosimilar competitor. Furthermore, with the shares down 20% from all-time highs in late-August, the stock’s valuation is returning to more attractive levels, particularly as we near a number of pipeline readouts, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $1,080 from $1,220 at Barclays
- Amgen to launch U.S. Eylea biosimilar, Reuters reports
- Regeneron price target lowered to $1,050 from $1,200 at Wells Fargo
- RBC would buy Regeneron on weakness with biosimilar Eylea priced in
- Regeneron announces three-year data for EYLEA HD Injection 8 mg study